SCHEDULE: Day One Biopharmaceuticals Tender Offer Update
Schedule 13D Amendment
AI Day1 LLC has tendered all its shares of Day One Biopharmaceuticals common stock in response to Servier Detroit Inc.'s tender offer.
Summary
- This filing is an amendment to a Schedule 13D, reporting changes related to the beneficial ownership of Day One Biopharmaceuticals, Inc. common stock.
- The reporting persons, including AI Day1 LLC, Access Industries Holdings LLC, Access Industries Management, LLC, and Len Blavatnik, collectively hold 12,929,322 shares, representing 12.52% of the outstanding common stock.
- On April 9, 2026, AI Day1 LLC tendered all of its shares of common stock as part of a tender offer by Servier Detroit Inc. to purchase all outstanding shares at $21.50 per share.
- The total number of outstanding shares of common stock as of February 19, 2026, was 103,297,691.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, primarily reporting on a completed tender offer and divestment by a significant shareholder, rather than providing new operational or financial performance data.
Positives
- The tender offer provides a cash exit for AI Day1 LLC's investment at $21.50 per share.
- The reporting persons have disclosed their beneficial ownership, adhering to SEC regulations.
Negatives
- The filing indicates a complete divestment of shares by AI Day1 LLC through the tender offer, suggesting a cessation of their investment in Day One Biopharmaceuticals.
Risks
- The tender offer is subject to certain terms and conditions, which could potentially impact the completion of the sale.
- There is a risk that not all shareholders may tender their shares, potentially affecting the overall transaction outcome.
Future Outlook
The filing primarily reports on a past event (tendering of shares) and does not contain forward-looking statements or guidance regarding the future operations of Day One Biopharmaceuticals.
Industry Context
StockSavvy.ai notes that this filing reflects a significant ownership change for Day One Biopharmaceuticals, driven by an acquisition tender offer. Such events are common in the biopharmaceutical sector as companies are acquired to gain access to their pipelines or technologies.
Stakeholder Impact
- Shareholders of Day One Biopharmaceuticals: Those who tender their shares will receive $21.50 in cash per share. Shareholders who do not tender may retain their shares, subject to the outcome of the tender offer and potential future delisting or merger events.
- Employees of Day One Biopharmaceuticals: The acquisition by Servier Detroit Inc. may lead to changes in employment, roles, or company structure.
- Creditors of Day One Biopharmaceuticals: The acquisition may impact existing debt obligations and covenants.
Next Steps
- Completion of the tender offer by Servier Detroit Inc. for all outstanding shares of Day One Biopharmaceuticals.
Key Dates
| Date | Description |
|---|---|
| 2021-06-09 | Initial Schedule 13D filing. |
| 2022-06-21 | Amendment No. 1 to Schedule 13D filed. |
| 2023-06-12 | Amendment No. 2 to Schedule 13D filed. |
| 2023-10-20 | Amendment No. 3 to Schedule 13D filed. |
| 2024-08-01 | Amendment No. 4 to Schedule 13D filed. |
| 2026-02-19 | Date as of which outstanding shares of Common Stock were reported. |
| 2026-02-24 | Date of filing of Issuer's Annual Report on Form 10-K. |
| 2026-03-26 | Date of filing of Schedule TO related to the tender offer. |
| 2026-04-09 | Date AI Day1 LLC tendered all of its shares of Common Stock. |
| 2026-04-13 | Date of signatures on Amendment No. 5 to Schedule 13D. |
Keywords
Schedule 13D, Day One Biopharmaceuticals, AI Day1 LLC, Servier Detroit Inc., Tender Offer, Beneficial Ownership, SEC Filing, Access Industries
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.